Farmako GmbH, A Subsidiary Of Agraflora Organics International Inc (OTCMKTS:AGFAF), Applies For GMP Certification In Europe: Seeks Manufacturing and Import Authorization

Farmako GmbH, a wholly-owned subsidiary of Agraflora Organics International Inc (OTCMKTS:AGFAF), has applied for EU-GMP (EU Good Manufacturing Practice) Certification. It also applied for the manufacturing and import authorization (MIA), which is permitted under the German Medical Products Act. It expects that this summer will complete processes for EU-GMP and MIA.

Commences cannabis medical products import

Farmako can commence the import of medical cannabis products from outside EEC (European Economic Community) on obtaining MIA and GMP Certification. It allows Farmako to ensure availability of cannabis medical products and scale up distribution in EU and Germany.

Germany established the highest standards in safety

Chief Executive Officer of Farmako, Katrin Eckmans, said Germany has established the highest standards for ensuring the safety of the medical patients in the world. It also helps to improve trust to patients, pharmacists, and physicians. Therefore, it is a challenge for businesses to establish a footprint in the German market place where a limited supply of medical cannabis products prevails. Farmako seeks MIA and EU-GMP certifications to improve the availability of medical cannabis products and provide high-quality products to patients in Germany.

Receives special authorization from BfArm

The German Federal Institute for Drugs and Medical Devices (“BfArM”) has given special authorization to Farmako to distribute medical cannabis flowers in the nation. The company can distribute medical cannabis flowers, which are subjected to ionizing radiation treatment. Therefore, EU-GMP certification, along with MIA, positions Farmako as a leader in the supply of cannabis medical products. The management of Farmako is of the view that additional supply options allow it to scale up its business by introducing a wide range of medical products in large volumes.

Health Canada approves to begin extraction

Health Canada has approved Sustainable Growth Strategic Capital Corp (SGS), a subsidiary of AgraFlora, to commence extraction at Greater Toronto facility. SGS is working with farmers in the Canadian cannabidiol business to maximize CBD extraction by optimizing the harvest. It has conducted a trial of hemp biomass extraction in March 2020. The company will use third-party services for hemp biomass extraction. It will sell isolate, distillate, and CBD crude oil.


Agraflora Organics International Inc (OTCMKTS:AGFAF) Pleased After Farmako’s Receives A Business License

Agraflora Organics International Inc (OTCMKTS:AGFAF) has disclosed the latest development regarding its subsidiary Farmako GmbH. The business guru says that Farmako will be free to engage in the distribution of medical cannabis flowers. These products have undergone the ionizing radiation treatment, and it seems great times lie ahead for this subsidiary.

The license and its impact

Agraflora has described the recent development as a major milestone for Farmako, saying that the German Federal Institute for Drugs and Medical Devices had done it a huge favor.

Reports indicate that the German medical cannabis marketplace has been encountering shortages in supply. A number of reasons have been cited to explain this undersupply, one of them being the scarcity of the EU-GMP certified cannabis flowers. What makes matters even worse is the fact that the exporting jurisdictions give tough conditions. One of them has been that one uses microbial sterilization before selling out products. Canada is one of these countries.

Eckmans and his perspective

The Chief Executive Officer of Farmako Katrin Eckmans says that it is a great achievement on their part to have secured the AMRadV license. He sees as a great stepping stone that will see them succeed in their quest to solve the major barriers that have been standing on their way to achieving massive business success.

Eckmans says that it feels great falling in the category of companies that can freely import and the sterilized cannabis flowers. The official believes that Farmako is on the right path, considering that it stands to benefit from the increased supply from various countries from around the globe.

The subsidiary is eyeing the significant growth in demand for the product and says that it will be taking full advantage of that.

Market observers say that Farmako stands to gain a huge deal from the German market. Reports indicate that the medical cannabis market in German may soon expand a great deal. It is projected that the expansion may get to the point of it becoming of the world’s biggest market places, focusing on the sale of cannabis products. Farmako says that it will uphold its efforts, which are targeted at making it more competitive as a licensed pharmaceutical wholesaler.


Agraflora Organics International Inc (OTCMKTS:AGFAF) Reveals Plan To Acquire Eviana Health Corporation

Agraflora Organics International Inc (OTCMKTS:AGFAF), an international firm that mainly focuses on cannabis growth has announced a plan to take over Eviana Health Corporation.

The company revealed that it plans to present an offer to Eviana Health Corporation’s shareholders for the purchase of the firm’s outstanding and issued common shares. Agraflora also revealed that its offer will allow Eviana Health shareholders to receive Agraflora’s common shares as part of the exchange.

Agraflora is prepared to give 1.694915 of its common shares to Eviana shareholders at $0.50 for every Eviana share. Additionally, Agraflora is prepared to strike a deal at $0.295 as the share price for its stock as on August 9 this year.

Eviana shareholders have an incentive to entertain the offer because it provides a 49.25% premium on the market price. It also provides them with access to a cannabis company that boasts of higher trading volumes and is also heavily focused on growth. Agraflora is expected to hold talks with Eviana over the next few days and will remain listed on the Canadian Stock Exchange if the takeover goes through.

Agraflora signs CBD distribution and commercialization Letter of intent

Agraflora announced on August 8 that it signed a non-binding letter of intent for the commercialization and distribution of CBD. The company revealed that it signed the deal with one of the largest food retailers in Canada, known as the Canadian Food Retailer.

Agraflora opted to engage with Canadian Food Retailer about the commercialization and distribution plans because it has a robust network of physical stores. The terms of the letter of intent indicate that the two companies will sign a Supply and Consulting deal, through which Canadian Food Retailer will receive packaged CBD-infused goods from Agraflora.

“We are elated to announce that this prominent Canadian Food Retailer has selected AgraFlora as a potential partner of choice for CBD commercialization and distribution,” stated Agraflora CEO, Brandon Boddy.

The CEO pointed out that his company was an attractive pick for Canadian Food Retailer because it has the right manufacturing capabilities, human capital, and assets. The company also boasts of ample scaling capacity for its manufacturing processes.

Pin It on Pinterest